Longbio Pharma (Suzhou) has reported positive topline results from a Phase I clinical trial of LP-003, a new long-acting anti-IgE antibody, for the treatment of allergic rhinitis.

The double-blind, randomised study has evaluated the pharmacokinetics, pharmacodynamics (free IgE levels) profile and safety of LP-003 in healthy subjects.

Subjects were randomised into five groups and administered intravenously with a single dose of 0. mg/kg, 1mg/kg, 3mg/kg, 6mg/kg and 10mg/kg, respectively.

A non-linear PK characteristic with T1/2 ranging from 46.3 days to 75.6 days was observed in patients, which is approximately 2~3 fold of omalizumab.

LP-003 also demonstrated high IgE binding affinity (>100 fold) without off-target binding and showed more potent FcεRI and FcεRII/CD23 inhibition in comparison with omalizumab.

Groups administered with 1 mg/Kg (except one with high baseline IgE level) to 10 mg/Kg showed suppression of free-IgE below the detection range for more than 70 days.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

LP-003 showed a good safety profile with no Grade 3 and above TEAE.

Longbio Pharma co-founder and inventor of omalizumab Dr Sun, Nai-chau said: “The positive results reinforce our belief in the best-in-class potential of LP-003 and its ability to address the urgent needs of patients suffering from allergic diseases, like allergic rhinitis.”

Based on the positive data from the Phase I study, the company has started Phase II clinical trials of LP-003.

Longbio is also planning to collaborate with industry stakeholders for developing and marketing LP-003 globally.

A Phase II study of LP-003 in chronic spontaneous urticaria is also ongoing.